Clinical Trials Directory

Trials / Sponsors / Elevar Therapeutics

Elevar Therapeutics

Industry · 9 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Phase 22026-05-01
CompletedA Study Comparing Four Different Rivoceranib Tablets in Healthy Participants
Healthy
Phase 12021-12-30
CompletedREFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other
FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement
Phase 1 / Phase 22020-09-02
TerminatedA Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoi
Adenoid Cystic Carcinoma
Phase 22020-01-22
TerminatedA Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
Phase 12019-11-18
TerminatedA Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gast
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Phase 1 / Phase 22018-10-01
CompletedA Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or M
Cancer
Phase 12017-12-22
CompletedA Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Par
Gastric Cancer, Gastric Adenocarcinoma
Phase 32017-03-14
CompletedDose-Escalation and Safety Trial of YN968D1
Cancer Patients With Solid Tumors
Phase 1 / Phase 22012-04-01